search
Back to results

Expanded Access to Zofin for Patients With COVID-19

Primary Purpose

Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome)

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Zofin
Sponsored by
Organicell Regenerative Medicine
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Covid19 focused on measuring Human, Exosomes, Human Amniotic Fluid

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria:

  1. Provide written informed consent
  2. Subjects age > 18 years at the time of signing the Informed Consent Form.
  3. Male or Female
  4. Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5
  5. Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population.

    The main symptoms of mild illness are:

    • low grade fever <38°C (37.5 to 37.9)
    • a dry cough
    • tiredness
    • feeling slightly breathless
    • muscle pain
    • headache
    • sore throat
    • diarrhea

    The main symptoms of moderate illness are:

    In addition to the symptoms patients may get with a mild illness, they may also experience:

    • fever ≥38°
    • a dry and more persistent cough several times an hour
    • tiredness and a need to stay in bed
    • feeling breathless when doing moderate exercise (such as walking upstairs)
    • muscle pain and aches and need to stay in bed
    • headache particularly if you are feeling hot
    • sore throat, soreness from coughing, but no pain
    • diarrhea
    • a dry mouth
  6. Adequate venous access
  7. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below:

    • Permanent Sterilization
    • Long-Acting Reversible Contraceptives (LARC)
    • Contraceptive Injection
    • Short-Acting Hormonal Methods
    • Barrier Methods
    • Emergency Contraception

    https://www.fda.gov/consumers/free-publications-women/birth-control

  8. Any male subject must agree to use contraceptives and not donate sperm during the study.
  9. Must agree to comply with all protocol requirements and be willing to complete all study visits

Exclusion Criteria:

  1. Patients who have moderate to severe respiratory distress syndrome due to COVID-19
  2. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.
  3. Inability to perform any of the assessments required.
  4. Active listing (or expected future listing) for transplant of any organ.
  5. Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
  6. History of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
  7. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    December 3, 2020
    Last Updated
    March 21, 2023
    Sponsor
    Organicell Regenerative Medicine
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04657406
    Brief Title
    Expanded Access to Zofin for Patients With COVID-19
    Official Title
    Expanded Access to Zofin for the Treatment of Patients With Mild to Moderate COVID-19 Due to SARS-Cov-2 for Outpatient and Inpatient Population
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organicell Regenerative Medicine

    4. Oversight

    5. Study Description

    Brief Summary
    This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.
    Detailed Description
    A human coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak worldwide. Common symptoms of COVID-19 include fever, cough, and shortness of breath. The majority of cases result in mild symptoms, but some can progress into pneumonia and multi-organ failure. According to the severity it is divided into mild, normal, severe and critically ill, which is associated with ICU admission and mortality. At present, the standard treatment of COVD-19 patients is oxygen therapy, mechanical ventilation, and medications to maintain blood pressure. As of today, no specific antiviral therapy is available for patients with COVID-19. Immune activation in some patients, and the appearance of cytokine storm syndrome (CSS) is one of the important causes of severe damage to lungs and other organs, which may lead to death. There is an urgent need to develop new interventions to suppress the excessive immune response in a timely manner during the course of disease, protect alveolar function, and reduce lung and systemic organ damage. Zofin is an acellular, minimally manipulated product, derived from human amniotic fluid (HAF). This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells. The product contains a mean concentration of 5.24x10^11 particles/mL with a mean mode size of 125.2nm. Surface marker analysis confirmed the presence of exosome associated proteins CD63, CD81, and CD9 in addition to high expression of CD133. The completed sequencing revealed 102 commonly expressed miRNA (with a 100-copy expression minimum). Bioinformatics analysis linked 63 miRNAs to 1216 RNA targets. Major players in the proinflammatory cytokine cascade found to be targeted by miRNA were discovered in Organicell's product include TNF, IL-6, and IL-8. Additionally, a broader array of pro-inflammatory cytokines is also targeted by the collection of miRNA such as FGF2, IFNB1, IGF1, IL36a, IL37, TGF-B2, VEGFA, CCL8, and CXCL12. It has been suggested in published research that inhibition or suppression of this pro-inflammatory cytokine cascade may reduce the severity of symptoms associated with elevated immune response. Furthermore, the miRNA was found to target 148 genes associated with immune response. The property of Zofin demonstrates the therapeutic potential as a suppressor of cytokine activation for the reduction of COVID-19 infection severity. This is an open label expanded access protocol to treat subjects using ZofinTM (OrganicellTM Flow) for treatment of mild to moderate COVID-19 due to SARS-Cov-2.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
    Keywords
    Human, Exosomes, Human Amniotic Fluid

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Zofin
    Other Intervention Name(s)
    Organicell Flow
    Intervention Description
    Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10^11 particles/mL.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Eligibility Criteria
    Inclusion Criteria: Provide written informed consent Subjects age > 18 years at the time of signing the Informed Consent Form. Male or Female Must have a clinical diagnosis of COVID-19 by the qualitative reverse-transcription polymerase chain reaction (RT-PCR), with at least one of mild or moderate COVID-19 clinical symptoms which are defined below in #5 Individuals with mild to moderately COVID-19 symptoms for outpatient and inpatient population. The main symptoms of mild illness are: low grade fever <38°C (37.5 to 37.9) a dry cough tiredness feeling slightly breathless muscle pain headache sore throat diarrhea The main symptoms of moderate illness are: In addition to the symptoms patients may get with a mild illness, they may also experience: fever ≥38° a dry and more persistent cough several times an hour tiredness and a need to stay in bed feeling breathless when doing moderate exercise (such as walking upstairs) muscle pain and aches and need to stay in bed headache particularly if you are feeling hot sore throat, soreness from coughing, but no pain diarrhea a dry mouth Adequate venous access For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment. The FDA-approved and cleared methods for birth control are listed below: Permanent Sterilization Long-Acting Reversible Contraceptives (LARC) Contraceptive Injection Short-Acting Hormonal Methods Barrier Methods Emergency Contraception https://www.fda.gov/consumers/free-publications-women/birth-control Any male subject must agree to use contraceptives and not donate sperm during the study. Must agree to comply with all protocol requirements and be willing to complete all study visits Exclusion Criteria: Patients who have moderate to severe respiratory distress syndrome due to COVID-19 Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion. Inability to perform any of the assessments required. Active listing (or expected future listing) for transplant of any organ. Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection. History of drug abuse (illegal "street" drugs except marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mari Mitrani, MD, PhD
    Phone
    888-963-7881
    Email
    clinicaltrials@organicell.com

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    32167524
    Citation
    Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum In: JAMA Intern Med. 2020 Jul 1;180(7):1031.
    Results Reference
    background
    PubMed Identifier
    31647191
    Citation
    Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 2020 Jan;9(1):28-38. doi: 10.1002/sctm.19-0205. Epub 2019 Oct 24.
    Results Reference
    background
    PubMed Identifier
    26868298
    Citation
    Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
    Results Reference
    background
    PubMed Identifier
    23883791
    Citation
    Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the "knowns" and "unknowns". J Formos Med Assoc. 2013 Jul;112(7):372-81. doi: 10.1016/j.jfma.2013.05.010. Epub 2013 Jul 21.
    Results Reference
    background
    PubMed Identifier
    32101510
    Citation
    Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Aug;296(2):E32-E40. doi: 10.1148/radiol.2020200642. Epub 2020 Feb 26.
    Results Reference
    background
    PubMed Identifier
    32053470
    Citation
    Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020 Jun;295(3):715-721. doi: 10.1148/radiol.2020200370. Epub 2020 Feb 13.
    Results Reference
    background
    PubMed Identifier
    32055945
    Citation
    Pan Y, Guan H, Zhou S, Wang Y, Li Q, Zhu T, Hu Q, Xia L. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020 Jun;30(6):3306-3309. doi: 10.1007/s00330-020-06731-x. Epub 2020 Feb 13.
    Results Reference
    background
    PubMed Identifier
    32105637
    Citation
    Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24.
    Results Reference
    background
    PubMed Identifier
    32150360
    Citation
    Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Aug 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK554776/
    Results Reference
    background
    PubMed Identifier
    31986264
    Citation
    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
    Results Reference
    background
    PubMed Identifier
    32007143
    Citation
    Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
    Results Reference
    background
    PubMed Identifier
    31995857
    Citation
    Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
    Results Reference
    background
    PubMed Identifier
    31986261
    Citation
    Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
    Results Reference
    background
    PubMed Identifier
    32031570
    Citation
    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
    Results Reference
    background
    PubMed Identifier
    32004427
    Citation
    Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
    Results Reference
    background
    PubMed Identifier
    18756809
    Citation
    Khamitov RA, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. Vopr Virusol. 2008 Jul-Aug;53(4):9-13. Russian.
    Results Reference
    background
    PubMed Identifier
    32065348
    Citation
    Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Liu JP. Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs. Chin J Integr Med. 2020 Apr;26(4):243-250. doi: 10.1007/s11655-020-3192-6. Epub 2020 Feb 17.
    Results Reference
    background
    Citation
    Center AM. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19). 2020
    Results Reference
    background
    Citation
    Hospital B. Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection. 2020.
    Results Reference
    background
    Citation
    Hospital BY, Shenyang Tonglian Group Co. L, Medicine Io, Biotechnology CAoMS, Hospital HC, University SP, University FAHoCM, University TSAHoHM, City NPsHoF, College FAHBM, University RHoW, Shenyang Tspsho and Hospital NC. The Clinical Study of Carrimycin on Treatment Patients With COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. 2020
    Results Reference
    background
    Citation
    Hospital T. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. 2020
    Results Reference
    background
    Citation
    Institut National de la Santé Et de la Recherche Médicale F. Trial of Treatments for COVID-19 in Hospitalized Adults. 2020
    Results Reference
    background
    Citation
    Kong TUoH and Hospital Authority HK. Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. 2020
    Results Reference
    background
    Citation
    Ltd. JQPC. Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe). 2020
    Results Reference
    background
    Citation
    Ltd. JQPC. Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia. 2020
    Results Reference
    background
    Citation
    Nanchang TNHo and Ascletis Pharmaceuticals Co. L. Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection. 2020
    Results Reference
    background
    Citation
    University FAHoZ and Ascletis Pharmaceuticals Co. L. Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection. 2020
    Results Reference
    background
    Citation
    QU J and Hospital R. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. 2020
    Results Reference
    background
    Citation
    University SAHoWM and WanBangDe Pharmaceutical Group Co. L. Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19). 2020
    Results Reference
    background
    Citation
    Hospital PUF. Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019. 2020
    Results Reference
    background
    Citation
    Marche UPd and Nord AOORM. Tocilizumab for SARS-CoV2 Severe Pneumonitis. 2020.
    Results Reference
    background
    PubMed Identifier
    33043164
    Citation
    Chiodini P, Arenare L, Piccirillo MC, Perrone F, Gallo C. A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan. Contemp Clin Trials Commun. 2020 Dec;20:100665. doi: 10.1016/j.conctc.2020.100665. Epub 2020 Oct 7.
    Results Reference
    background
    Citation
    Hospital T. A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. 2020
    Results Reference
    background
    Citation
    Hospital T. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients. 2020.
    Results Reference
    background
    Citation
    Peng Z, Ltd TBTC and Hospital Z. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia. 2020
    Results Reference
    background
    Citation
    Allergy NIo and Diseases I. Adaptive COVID-19 Treatment Trial. 2020
    Results Reference
    background
    Citation
    Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Severe Coronavirus Disease (COVID-19). 2020
    Results Reference
    background
    Citation
    Sciences G. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS- 5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment. 2020.
    Results Reference
    background
    Citation
    University CM. Severe 2019-nCoV Remdesivir RCT. 2020
    Results Reference
    background
    Citation
    University CM and Sciences CAoM. Mild/Moderate 2019-nCoV Remdesivir RCT. 2020
    Results Reference
    background
    Citation
    Center SPHC. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV ). 2020
    Results Reference
    background
    Citation
    Minnesota Uo. Post-exposure Prophylaxis for SARS-Coronavirus-2. 2020.
    Results Reference
    background
    Citation
    National Institute of Respiratory Diseases M and Sanofi. Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial). 2020.
    Results Reference
    background
    Citation
    Hospital HPPs. Tetrandrine Tablets Used in the Treatment of COVID-19. 2020
    Results Reference
    background
    Citation
    Sciences CAoCM. Yinhu Qingwen Decoction for the Treatment of Mild Common CoVID-19. 2020.
    Results Reference
    background
    Citation
    Wang Z, Hospital WL, University TFAHoDM, Hospital TPs, Science NCUo, Hospital TA, Hospital JEFG and Sciences CAoCM. Yinhu Qingwen Granula for the Treatment of Severe CoVID-19. 2020.
    Results Reference
    background
    Citation
    Hospital MG, Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital MG, Hospital X, Fondazione IRCCS Ca' Granda OMP and Hospital N. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital X and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection. 2020.
    Results Reference
    background
    Citation
    Hospital X, Hospital MG and Fondazione IRCCS Ca' Granda OMP. Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. 2020
    Results Reference
    background
    Citation
    NeuroRx I and SA RTH. Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress. 2020
    Results Reference
    background
    Citation
    OncoImmune I. CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment. 2020.
    Results Reference
    background
    Citation
    Wuhan Union Hospital C. Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients. 2020
    Results Reference
    background
    Citation
    Hospital T. The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital PUMC, Tongji Hospital of Tongji Medical College HUoS and Technology. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia. 2020.
    Results Reference
    background
    Citation
    Science PHAtWUo, Technology and Wuhan Hamilton Bio-technology Co. L. Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus. 2020
    Results Reference
    background
    Citation
    Hospital T-D. Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia. 2020
    Results Reference
    background
    Citation
    Southeast University C. Immunoregulatory Therapy for 2019-nCoV. 2020.
    Results Reference
    background
    Citation
    Pulmotect I. The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. 2020
    Results Reference
    background
    Citation
    Pulmotect I. The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID- 19 in Adults Positive for SARS-CoV-2 Infection. 2020
    Results Reference
    background
    Citation
    Pharmaceuticals R and Sanofi. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. 2020
    Results Reference
    background
    Citation
    Peng Z and Hospital Z. Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia. 2020.
    Results Reference
    background
    Citation
    University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. 2020
    Results Reference
    background
    Citation
    University FAHoWM, University SAHoWM and Hospital WC. The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19. 2020
    Results Reference
    background
    Citation
    University FAHoFM. Fingolimod in COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital BCY. Efficacy and Safety of Corticosteroids in COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital PUMC, Hospital Z, Hospital Z and University RHoW. Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure. 2020.
    Results Reference
    background
    Citation
    Hospital T. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia. 2020.
    Results Reference
    background
    Citation
    Hospital B, CELL V, GENE ENGINEERING CORP. L, China, Wuhan Huoshenshan Hospital W, China, Hospital TH, Hospital STPs, Fifth Affiliated Hospital SY-SU, Wuhan Union Hospital C and Hospital WC. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19). 2020
    Results Reference
    background
    Citation
    Hospital B, Innovative Precision Medicine Group H, China., Wuhan Huoshenshan Hospital W, China, Hospital TH, CELL V, GENE ENGINEERING CORP. L, China, Hospital STPs and Fifth Affiliated Hospital SY-SU. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus. 2020.
    Results Reference
    background
    Citation
    CAR-T Biotechnology Co. L. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. 2020.
    Results Reference
    background
    Citation
    Wuhan Union Hospital C and Wuhan Hamilton Bio-technology Co. L, China. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia. 2020.
    Results Reference
    background
    Citation
    Arabia SC. Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells. 2020.
    Results Reference
    background
    Citation
    Brasil A, Ltda CPC and Cruz HV. Mesenchymal Stem Cell NestCell® to Treat Patients With Severe COVID-19 Pneumonia. 2020
    Results Reference
    background
    Citation
    Inc. TSCB. Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2. 2020
    Results Reference
    background
    Citation
    University Xm and University FAHoXM. NK Cells Treatment for Novel Coronavirus Pneumonia. 2020
    Results Reference
    background
    Citation
    Tasly Pharmaceuticals I. The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19. 2020
    Results Reference
    background
    Citation
    Hospital T. A Pilot Study of Sildenafil in COVID-19. 2020.
    Results Reference
    background
    Citation
    Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization. 2020.
    Results Reference
    background
    Citation
    Minnesota Uo. Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization. 2020.
    Results Reference
    background
    Citation
    Hospital S, Medicine HHoTC, Hospital JNPs and Hospital T. Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu. 2020
    Results Reference
    background
    PubMed Identifier
    22718279
    Citation
    Munoz-Fernandez R, Prados A, Leno-Duran E, Blazquez A, Garcia-Fernandez JR, Ortiz-Ferron G, Olivares EG. Human decidual stromal cells secrete C-X-C motif chemokine 13, express B cell-activating factor and rescue B lymphocytes from apoptosis: distinctive characteristics of follicular dendritic cells. Hum Reprod. 2012 Sep;27(9):2775-84. doi: 10.1093/humrep/des198. Epub 2012 Jun 20.
    Results Reference
    background
    PubMed Identifier
    24428376
    Citation
    Castro-Manrreza ME, Mayani H, Monroy-Garcia A, Flores-Figueroa E, Chavez-Rueda K, Legorreta-Haquet V, Santiago-Osorio E, Montesinos JJ. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev. 2014 Jun 1;23(11):1217-32. doi: 10.1089/scd.2013.0363. Epub 2014 Feb 24.
    Results Reference
    background
    PubMed Identifier
    26689863
    Citation
    Fontaine MJ, Shih H, Schafer R, Pittenger MF. Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. Transfus Med Rev. 2016 Jan;30(1):37-43. doi: 10.1016/j.tmrv.2015.11.004. Epub 2015 Dec 1.
    Results Reference
    background
    PubMed Identifier
    29362849
    Citation
    Najar M, Krayem M, Merimi M, Burny A, Meuleman N, Bron D, Raicevic G, Lagneaux L. Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts. Inflamm Res. 2018 Jun;67(6):467-477. doi: 10.1007/s00011-018-1131-1. Epub 2018 Jan 23.
    Results Reference
    background
    PubMed Identifier
    29895977
    Citation
    Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018 Aug;14(8):493-507. doi: 10.1038/s41581-018-0023-5.
    Results Reference
    background
    PubMed Identifier
    29807782
    Citation
    Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Mol Ther. 2018 Jul 5;26(7):1610-1623. doi: 10.1016/j.ymthe.2018.05.009. Epub 2018 May 25.
    Results Reference
    background
    PubMed Identifier
    25552688
    Citation
    Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ Res. 2015 Jan 2;116(1):12-5. doi: 10.1161/CIRCRESAHA.114.305495. No abstract available.
    Results Reference
    background
    PubMed Identifier
    22237468
    Citation
    Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev Rep. 2013 Feb;9(1):65-79. doi: 10.1007/s12015-011-9345-4.
    Results Reference
    background
    PubMed Identifier
    22008910
    Citation
    Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012 Jan;20(1):14-20. doi: 10.1038/mt.2011.211. Epub 2011 Oct 18.
    Results Reference
    background
    PubMed Identifier
    29254275
    Citation
    Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget. 2017 May 23;8(60):102600-102616. doi: 10.18632/oncotarget.18126. eCollection 2017 Nov 24.
    Results Reference
    background
    PubMed Identifier
    19135507
    Citation
    Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009 Mar 15;433(1-2):1-7. doi: 10.1016/j.gene.2008.12.008. Epub 2008 Dec 24.
    Results Reference
    background
    Citation
    Cajal FplIBdHURy, III IdSC and pulmonar FdAalIslH. Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies. 2019
    Results Reference
    background
    Citation
    Hospital D, University tRIoSotTMM, University CsHoCM, Maternal C and Hospital CH. Stem Cells for Bronchopulmonary Dysplasia. 2017.
    Results Reference
    background
    Citation
    Ltd. MC. PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants. 2018
    Results Reference
    background
    Citation
    University CsHoCM. Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia. 2018.
    Results Reference
    background
    Citation
    University CsHoCM. Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia. 2019
    Results Reference
    background
    Citation
    Center MDAC and Foundation K. Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies. 2017
    Results Reference
    background
    PubMed Identifier
    32493473
    Citation
    Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, O'Kane C, McAuley DF. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials. 2020 Jun 3;21(1):462. doi: 10.1186/s13063-020-04416-w.
    Results Reference
    background
    Citation
    University SY-s. Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS. 2018.
    Results Reference
    background
    Citation
    Clinic M. Mesenchymal Stem Cell Therapy for Lung Rejection. 2014
    Results Reference
    background
    Citation
    Clinic M. Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD). 2020.
    Results Reference
    background
    Citation
    Mesoblast I and Mesoblast L. PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). 2008.
    Results Reference
    background
    Citation
    Clinica Universidad de Navarra UdN. Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis. 2013
    Results Reference
    background
    Citation
    Dai J, Southwest Hospital C and Sciences CAo. A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells. 2014.
    Results Reference
    background
    Citation
    Hare JM, Lester T, Foundation SS, The Emmes Company L and Miami Uo. Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER). 2013.
    Results Reference
    background
    Citation
    Hospital TPC and Institute MMR. A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis. 2010.
    Results Reference
    background
    Citation
    Dai J, Southwest Hospital C, Hospital NC and Sciences CAo. A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells. 2016.
    Results Reference
    background
    Citation
    Glassberg M and Miami Uo. Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis. 2016.
    Results Reference
    background
    Citation
    Glassberg M and Miami Uo. Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma. 2017
    Results Reference
    background
    Citation
    Hare JM and Miami Uo. Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis. 2020.
    Results Reference
    background
    PubMed Identifier
    36549988
    Citation
    Roesch EA, Bonfield TL, Lazarus HM, Reese J, Hilliard K, Hilliard J, Khan U, Heltshe S, Gluvna A, Dasenbrook E, Caplan AI, Chmiel JF. A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis. J Cyst Fibros. 2023 May;22(3):407-413. doi: 10.1016/j.jcf.2022.12.001. Epub 2022 Dec 20.
    Results Reference
    background
    Citation
    Hospital LPs. Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension. 2019
    Results Reference
    background
    PubMed Identifier
    21157345
    Citation
    Da Sacco S, De Filippo RE, Perin L. Amniotic fluid as a source of pluripotent and multipotent stem cells for organ regeneration. Curr Opin Organ Transplant. 2011 Feb;16(1):101-5. doi: 10.1097/MOT.0b013e3283424f6e.
    Results Reference
    background

    Learn more about this trial

    Expanded Access to Zofin for Patients With COVID-19

    We'll reach out to this number within 24 hrs